TY - JOUR
T1 - Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma
AU - Nakaoka, Kazunori
AU - Ohno, Eizaburo
AU - Kawabe, Naoto
AU - Kuzuya, Teiji
AU - Funasaka, Kohei
AU - Nakagawa, Yoshihito
AU - Nagasaka, Mitsuo
AU - Ishikawa, Takuya
AU - Watanabe, Ayako
AU - Tochio, Takumi
AU - Miyahara, Ryoji
AU - Shibata, Tomoyuki
AU - Kawashima, Hiroki
AU - Hashimoto, Senju
AU - Hirooka, Yoshiki
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/1
Y1 - 2023/1
N2 - Pancreatic ductal adenocarcinoma (PDAC) can be treated with surgery, chemotherapy, and radiotherapy. Despite medical progress in each field in recent years, it is still insufficient for managing PDAC, and at present, the only curative treatment is surgery. A typical pancreatic cancer is relatively easy to diagnose with imaging. However, it is often not recommended for surgical treatment at the time of diagnosis due to metastatic spread beyond the pancreas. Even if it is operable, it often recurs during postoperative follow-up. In the case of PDAC with a diameter of 10 mm or less, the 5-year survival rate is as good as 80% or more, and the best index for curative treatment is tumor size. The early detection of pancreatic cancer with a diameter of less than 10 mm or carcinoma in situ is critical. Here, we provide an overview of the current status of diagnostic imaging features and genetic tests for the accurate diagnosis of early-stage PDAC.
AB - Pancreatic ductal adenocarcinoma (PDAC) can be treated with surgery, chemotherapy, and radiotherapy. Despite medical progress in each field in recent years, it is still insufficient for managing PDAC, and at present, the only curative treatment is surgery. A typical pancreatic cancer is relatively easy to diagnose with imaging. However, it is often not recommended for surgical treatment at the time of diagnosis due to metastatic spread beyond the pancreas. Even if it is operable, it often recurs during postoperative follow-up. In the case of PDAC with a diameter of 10 mm or less, the 5-year survival rate is as good as 80% or more, and the best index for curative treatment is tumor size. The early detection of pancreatic cancer with a diameter of less than 10 mm or carcinoma in situ is critical. Here, we provide an overview of the current status of diagnostic imaging features and genetic tests for the accurate diagnosis of early-stage PDAC.
UR - http://www.scopus.com/inward/record.url?scp=85146802887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146802887&partnerID=8YFLogxK
U2 - 10.3390/diagnostics13020215
DO - 10.3390/diagnostics13020215
M3 - Review article
AN - SCOPUS:85146802887
SN - 2075-4418
VL - 13
JO - Diagnostics
JF - Diagnostics
IS - 2
M1 - 215
ER -
